aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Vir Biotechnology, founded to harness immunology expertise, focuses on developing and commercializing therapeutics for viral and bacterial diseases. The company's core mission is to transform lives by powering the immune system through innovative treatments. Vir's product offerings include a robust pipeline of monoclonal antibodies (mAbs) optimized and engineered using artificial intelligence, targeting infectious and viral-associated diseases. Their market focus is primarily in California, addressing significant unmet medical needs.
Notable figures affiliated with Vir Biotechnology include leading scientists and industry experts who drive its research and development efforts. The company has attracted significant investment from prominent venture capital firms and strategic partners, bolstering its financial and operational capabilities. Key achievements include the development of several promising therapeutic candidates currently in clinical trials. Vir's impact is marked by its commitment to scientific innovation and potential to deliver groundbreaking treatments for infectious diseases.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Therapeutics, Medicines
Technology
AI, Biotech
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Vir Biotechnology founded?
Vir Biotechnology was founded in 2016.
Where is Vir Biotechnology’s headquarters located?
Vir Biotechnology’s headquarters is located in San Francisco, CA, US.
When was Vir Biotechnology’s last funding round?
Vir Biotechnology’s most recent funding round was for $50M (USD) in October 2023.
How many employees does Vir Biotechnology have?
Vir Biotechnology has 576 employees as of Feb 6, 2024.
How much has Vir Biotechnology raised to-date?
As of July 05, 2023, Vir Biotechnology has raised a total of $908.6M (USD) since Oct 3, 2023.
Add Comparison
Total Raised to Date
$908.6M
USD
Last Update Oct 3, 2023
Last Deal Details
$50M
USD
Oct 3, 2023
Grant
Total Employees Over Time
576
As of Feb 2024
Vir Biotechnology Address
499 Illinois Street
Suite 500
San Francisco,
California
94158
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts